Mazowiecki Szpital Brodnowski Sp. z o.o.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The Neurology Clinic at Mazowiecki Szpital Brodnowski is conducting studies aimed at improving outcomes after myocardial infarction and in patients with acute heart failure. Trials evaluate novel agents such as dapagliflozin and intravenous iron therapy to reduce mortality, hospital readmission, and enhance quality of life.
- Recent myocardial infarction
- Acute heart failure
- Venous thromboembolism
- Iron deficiency after MI
These investigations reflect the site’s commitment to advancing cardiovascular care alongside its neurological focus.
Neoplasms
Research at the clinic includes trials in ovarian cancer and related gynecologic malignancies, assessing maintenance strategies with agents like rucaparib and dose‑equivalence of bevacizumab. The goal is to prolong progression‑free survival and improve patient outcomes after frontline chemotherapy.
- Ovarian epithelial cancer
- Fallopian tube cancer
- Peritoneal carcinoma
- High‑grade serous ovarian cancer
The oncology program integrates targeted therapies with immunotherapy to address high‑risk disease.
Hormonal diseases
The site evaluates new treatments for endocrine disorders such as acromegaly and Cushing's disease. One study investigates the effect of Lu AG13909 on hormone levels, safety, and tolerability, aiming to provide better disease control for patients with these rare conditions.
- Acromegaly
- Cushing's disease
These trials support the development of therapies that normalize hormonal excess.
Nervous System Diseases
A broad portfolio of neurological studies targets movement and neurodegenerative disorders. Ongoing work in Parkinson's disease explores disease‑modifying antibodies, while gene‑therapy approaches are tested in Huntington's disease. Trials also address Frontotemporal dementia with progranulin mutations and assess slowing of disability in progressive supranuclear palsy.
- Parkinson's disease
- Huntington's disease
- Frontotemporal dementia
- Progressive supranuclear palsy
Innovative delivery methods, including intracerebral infusion, are being evaluated to enhance therapeutic efficacy.
Congenital, Hereditary, and Neonatal Diseases
The clinic’s research includes hereditary neurodegenerative conditions. Studies focus on disorders caused by a genetic mutation, such as progranulin‑related frontotemporal dementia and the inherited expansion seen in Huntington’s disease, aiming to modify disease progression early in the disease course.
- Huntington's disease
- Frontotemporal dementia with progranulin mutation
These efforts highlight the site’s dedication to precision medicine for inherited neurological disorders.
Bacterial Infections and Mycoses
While the primary focus is neurological, the institution is preparing exploratory studies on bacterial infections and fungal diseases, evaluating safety of novel antimicrobial agents in hospitalized patients.
- Exploratory antimicrobial safety study
- Fungal infection monitoring trial
Future protocols may integrate infection control with neurology patient management.
Not possible to specify
The research environment at the clinic supports multidisciplinary research, allowing investigators to cross traditional therapeutic boundaries and address complex patient needs.
- Cardiovascular
- Oncology
- Neurology
- Endocrinology
This flexibility enables the site to respond quickly to emerging scientific opportunities.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 7 therapeutic areas and 15 of 25 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 9 by active trials.
- 1Agencja Badań Medycznych2active
lock +8 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Agencja Badań Medycznych2trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Mazowiecki Szpital Brodnowski Sp. z o.o.
lock Showing 1 of 15 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early-Stage Parkinson’s Disease | F. Hoffmann-La Roche AG | Phase III | Recruiting | Jan 2026 | — |
IMP list
lock Showing 1 of 25 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Prasinezumab | 2 | Unknown | 2021-05-11 | 2026-01-15 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.